PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis
This meta-analysis validated the benefit of adding immunotherapy to platinum-based chemotherapy with respect to PFS. dMMR patients gain advantages from the inclusion of either anti-PD-1 or anti-PD-L1 agents, whereas pMMR patients only experience this benefit when treated with anti-PD-1 agents.
Authors
- Mariana Carvalho Gouveia (ORCID: https://orcid.org/0000-0001-8194-7594)
- Mariana Scaranti (ORCID: https://orcid.org/0000-0001-7713-0100)
- Felippe Lazar Neto (ORCID: https://orcid.org/0000-0002-0051-9537)
- Mateus Trinconi Cunha (ORCID: https://orcid.org/0000-0001-9101-8553)
- Renata Colombo Bonadio (ORCID: https://orcid.org/0000-0001-5818-922X)
- M. Trento
Institutions
- Sunnybrook Health Science Centre (CA)
- Universidade de São Paulo (BR)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- Instituto do Câncer do Estado de São Paulo (BR)
- D’Or Institute for Research and Education (BR)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-04-01
- DOI
- https://doi.org/10.3332/ecancer.2025.1884
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70